Amgen Inc.

Celgene Corporation

Alector LLC

Atara Biotherapeutics, Inc.

Other

Jeonghoon Sun

Mark Leo Michaels

Yue-Sheng Li

Randy Ira Hecht

Edward John Belouski

Agnes Eva Hamburger

Jing M Xu

Murielle Marie Ellison

Lei-Ting Tony Tam

Xiaolan Zhou

Keith Soo-Nyung Kwak

Hui-Quan Han

Kandasamy Hariharan

Huiquan Han

Henry Chan

Thomas Charles Boone

Rohini Deshpande

Mei-Mei Tsai

Mahan Abbasian

Randal Robert Ketchem

Kenneth William Walker

Hosung Min

David Mikolon

Susie Miki Harris

Hua Long

Seog Joon Han

Ji Lu

John Lu

Christina Valerie Trout

Yang Li

Arnon Rosenthal

Ian Nevin Foltz

Chadwick Terence King

Wenyan Shen

Heather K Raymon

Shaw-Fen Sylvia Hu

Colin V Gegg

Wei-Hsien Ho

Tina Schwabe

Spencer Liang

Brydon L Bennett

Marilyn Kehry

Hq Han

Philip Chamberlain

Colin Victor Gegg, Jr

Jason Charles O'Neill

Herve Rhinn

Ilaria Tassi

Angie Grace Yee

Philip Ling Kong

Muhammad Abbas Alhawagri

Ananya Mitra

Jing Xu

Francesco Galimi

Haralambos Hadjivassiliou

Carlo Steven Santos

Samuel Nalle

Andrew Wurmser

Thomas M Dillon

Laure Escoubet

Gustavo Fenalti

Monica Wai Ling Leung

Konstantinos Mavrommatis

Roli Khattri

Monica Leung

Pilgrim Jackson

Sanaa Torres

Karpagam Srinivasan

Santiago Viveros Salazar

Daniel P Bermingham

Francesca Cignarella

Klaus-Dieter Heger

Sharmistha Acharya

Dan Zhu

Rashmi Bankoti

Ho Cho

Jeffrey Johnson

Marc W Retter

Roger Fachini

Jeffrey C Johnson

Lawrence Dearth

Lisa Morrison

Margaret Speed Ricci

Jette Wypych

Pavel Bondarenko

Alain Balland

Martin J Allen

Amy Guo

Christopher John Vezina

Susie M Harris

Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.

Engineering of an antibody for tumor-selective binding of CD47

Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-α (SIRPα) and modulate the activity of SIRPα.

SIRP-α binding proteins and methods of use thereof

The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

Siglec-9 ECD fusion molecules

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Methods of treating non-alcoholic steatohepatitis using FGF21 mutants

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

Stabilized receptor polypeptides and uses thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A4A antibodies and methods of use thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-&#x3b1; (SIRP&#x3b1;) and modulate the activity of SIRP&#x3b1;.

SIRP-&#x3b1; binding proteins and methods of use thereof

Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.

Antibodies with low immunogenicity and uses thereof

Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof. Methods of treating B cell-related disorders associated with BCMA expression in a patient in need thereof are provided, comprising administering to the patient a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.

BCMA-binding antibodies and uses thereof

The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.

Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

PD-1 binding proteins and methods of use thereof

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.

Variant activin receptor

Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof

There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods

The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.

Methods of treating of diabetes and obesity using FGF21 mutants

Growing community of inventors

Thousand Oaks, CA, United States of America

Jeonghoon Sun